Get access

Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease

Authors

  • Natália Pessoa Rocha MSc,

    1. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    2. Laboratório de Neurofarmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author
  • Antônio Lúcio Teixeira MD, PhD,

    1. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author
  • Paula Luciana Scalzo PhD,

    1. Laboratório de Neurobiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author
  • Izabela Guimarães Barbosa MD, PhD,

    1. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author
  • Mariana Soares de Sousa MD,

    1. Departamento de Neurologia e Neurocirugia, Santa Casa de Belo Horizonte Hospital, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author
  • Isabela Boechat Morato,

    1. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    2. Laboratório de Neurofarmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author
  • Érica Leandro Marciano Vieira PhD,

    1. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author
  • Paulo Pereira Christo MD, PhD,

    1. Departamento de Neurologia e Neurocirugia, Santa Casa de Belo Horizonte Hospital, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author
  • András Palotás MD, PhD,

    Corresponding author
    1. Asklepios-Med (private medical practice and research center), Szeged, Hungary
    • Correspondence to: Dr. András Palotás, Asklepios-Med, H-6722 Szeged, Kossuth Lajos sgt. 23, Hungary; palotas@asklepios-med.eu

    Search for more papers by this author
  • Helton José Reis PhD

    1. Laboratório de Neurofarmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    Search for more papers by this author

  • Funding agencies: CNPq, CAPES, FAPEMIG and Asklepios-Med. NPR is a CNPq SWO scholarship recipient. IGB and ELMV are post-doctoral fellows of CAPES and CNPq, respectively. IBM holds a CNPq undergraduate grant. ALT and HJR are awarded a CNPq fellowship. AP is funded by Asklepios-Med.

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

ABSTRACT

Inflammatory mechanisms have been implicated in a series of neuropsychiatric conditions, including behavioral disturbances, cognitive dysfunction, and affective disorders. Accumulating evidence also strongly suggests their involvement in the pathophysiology of Parkinson's disease (PD). This study aimed to evaluate plasma levels of inflammatory biomarkers, and their association with cognitive performance and other non-motor symptoms of PD. PD patients and control individuals were subjected to various psychometric tests, including the Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), and Beck's Depression Inventory (BDI). Biomarker plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). PD patients exhibited worse performance on MMSE and the programming task of FAB, and presented higher soluble tumor necrosis factor receptor (sTNFR) plasma levels than control individuals. Among PD patients, increased sTNFR1 and sTNFR2 concentrations were associated with poorer cognitive test scores. After multiple linear regression, sTNFR1 and education remained a significant predictor for FAB scores. Our data suggest that PD is associated with a proinflammatory profile, and sTNFRs are putative biomarkers of cognitive performance, with elevated sTNFR1 levels predicting poorer executive functioning in PD patients. © 2013 International Parkinson and Movement Disorder Society

Get access to the full text of this article

Ancillary